Vancouver, Canada, April 15, 2026 (GLOBE NEWSWIRE) — Clearmind Medication Inc. (Nasdaq: CMND) (“Clearmind” or the “Company”), a clinical-stage biotech firm centered on the invention and growth of novel, non-hallucinogenic, second technology, neuroplastogen-derived therapeutics to resolve main under-treated well being issues, at this time introduced that its unbiased Information and Security Monitoring Board (“DSMB”) has accomplished its assessment and issued a optimistic suggestion to proceed the continued FDA-approved Part I/IIa scientific trial of CMND-100 for the remedy of Alcohol Use Dysfunction (“AUD”).
The optimistic DSMB suggestion follows the profitable completion of the third cohort and is predicated on encouraging top-line security information demonstrating that CMND-100 was nicely tolerated with no critical hostile occasions reported. These outcomes reinforce the favorable security and tolerability profile noticed in earlier cohorts.
Because of this, the Firm will now proceed to the fourth cohort of the trial and can improve the examined dose of its proprietary drug candidate CMND-100 to 160mg.
The Part I/IIa scientific trial is a multinational, multicenter research designed to judge the security, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, the Firm’s proprietary non-hallucinogenic MEAI-based oral drug candidate, in sufferers with reasonable to extreme AUD.
About Clearmind Medication Inc.
More Read
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech firm centered on the invention and growth of non-hallucinogenic, second technology, neuroplastogen-derived therapeutics to resolve widespread and underserved well being issues, together with alcohol use dysfunction. Its main goal is to analysis and develop psychedelic-based compounds and try and commercialize them as regulated medicines, meals, or dietary supplements.
The Firm’s mental portfolio at present consists of 19 patent households, together with 31 granted patents. The Firm intends to hunt further patents for its compounds at any time when warranted and can stay opportunistic relating to the acquisition of further mental property to construct its portfolio.
Shares of Clearmind are listed for buying and selling on Nasdaq below the image “CMND.”
More Read
For additional data, go to: https://www.clearmindmedicine.com or contact:
Ahead-Wanting Statements:
This press launch accommodates “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act and different securities legal guidelines. Phrases corresponding to “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and related expressions or variations of such phrases are meant to establish forward-looking statements. For instance, the Firm is utilizing forward-looking statements when it discusses the timing and progress of its scientific trials. Ahead-looking statements should not historic details, and are primarily based upon administration’s present expectations, beliefs and projections, lots of which, by their nature, are inherently unsure. Such expectations, beliefs and projections are expressed in good religion. Nevertheless, there may be no assurance that administration’s expectations, beliefs and projections will probably be achieved, and precise outcomes could differ materially from what’s expressed in or indicated by the forward-looking statements. Ahead-looking statements are topic to dangers and uncertainties that might trigger precise efficiency or outcomes to vary materially from these expressed within the forward-looking statements. For a extra detailed description of the dangers and uncertainties affecting the Firm, reference is made to the Firm’s experiences filed every now and then with the Securities and Trade Fee (“SEC”), together with, however not restricted to, the dangers detailed within the Firm’s annual report on Type 20-F for the fiscal yr ended October 31, 2025 and subsequent filings with the SEC. Ahead-looking statements communicate solely as of the date the statements are made. The Firm assumes no obligation to replace forward-looking statements to replicate precise outcomes, subsequent occasions or circumstances, adjustments in assumptions or adjustments in different components affecting forward-looking data besides to the extent required by relevant securities legal guidelines. If the Firm does replace a number of forward-looking statements, no inference needs to be drawn that the Firm will make further updates with respect thereto or with respect to different forward-looking statements. References and hyperlinks to web sites have been offered as a comfort, and the data contained on such web sites shouldn’t be integrated by reference into this press launch. Clearmind shouldn’t be liable for the contents of third-party web sites.
